Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 6/20 | 0.36 |
| ▸ | CDK8 | P49336 | 6/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922880 | 0.85 | GRM2 (0.42) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14239922 | 0.82 | USP30 (0.41) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14239049 | 0.81 | TDP1 (0.41) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14239848 | 0.80 | NPC1 (0.41) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14239823 | 0.79 | TDP1 (0.38) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL15816798 | 0.79 | TDP1 (0.38) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14239047 | 0.77 | TDP1 (0.48) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14238834 | 0.77 | TDP1 (0.48) | L3MBTL1TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL14239370 | 0.77 | MAPK1 (0.41) | L3MBTL1ALDH1A1KMT2AMAPK1RAB9A | |
| SCHEMBL14239838 | 0.77 | MAPK1 (0.43) | L3MBTL1ALDH1A1KMT2AMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | L3MBTL1 3852/4885TDP1 3830/4885KDM4E 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.